ArticleCurrent protein & peptide science2026
Network Pharmacology and Experiments to Verify the Effect and Potential Mechanism of Baicalein on Osteoporosis.
Article in Current protein & peptide science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Nutrition and Metabolism in Musculoskeletal Diseases.Current protein & peptide science · 2026Article
- Deciphering oligomeric proanthocyanidins' dual osteoprotective mechanisms at single-cell resolution:Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundBaicalein (BN), a potent flavonoid derived from Scutellaria, exhibits an array of noteworthy attributes, such as anti-inflammatory, antibacterial, and antipyretic properties. Furthermore, its potential in treating osteoporosis has been highlighted. Nonetheless, the exact modes of action responsible for its therapeutic effects remain obscure. Hence, this study aims to elucidate the improvement effect of BN on OVX rats and explore its potential mechanism of action in treating osteoporosis through a comprehensive strategy that integrates network pharmacology and rigorous animal experiments.
methodsThe potential protein targets and OP disease targets in BN are analyzed using the protein database. The protein interaction diagram is constructed by Cytoscape3.7.2 software, and binding energy is used to evaluate the binding activity between BN and core targets, and some key genes are verified by protein experiments. RESULTS AND DISCUSSION: Topology analysis and prediction reveal that osteoporosis (OP) is associated with more than ten core target proteins. Notably, NAD-dependent deacetylase sirtuin 1 (SIRT1), Androgen Receptor (AR), Estrogen Receptor beta (ESR1), and Cyclooxygenase-2 (PTGS2) emerge as pivotal proteins in the treatment of osteoporosis with BN. The biological process underlying BN treatment of osteoporosis primarily involves the regulation of sex hormone levels, autophagy, inflammatory response, and reactive oxygen metabolism. Moreover, the signaling pathways involved are predominantly the PI3K-Akt pathway, AMPK pathway, and estrogen signaling pathway. Subsequent animal experiments corroborate these findings by demonstrating that BN significantly enhances the expression levels of SIRT1, AR, and ESR1 in tissues, while concurrently reducing the protein expression of PTGS2. This multifaceted approach ultimately achieves the desired therapeutic outcome of osteoporosis treatment.
conclusionIn summary, this study has validated the therapeutic effect of BN on OP and analyzed multiple potential therapeutic targets of BN for osteoporosis, which provides new ideas for further clinical treatment and experimental research of BN.
Indexed as
Identifiers
40108897What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.